By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease ...
Muscular Dystrophy Association-led research collaboration with FSHD Society, LGMD2L Foundation, and Parent Project Muscular ...
Genethon highlights latest developments in gene therapies for diseases once considered incurable, including Duchenne muscular dystrophy ...
Sarepta’s blockbuster gene therapy has come under scrutiny following a string of patient deaths.
Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy January 26, ...
Sarepta says effects of Duchenne muscular dystrophy gene therapy were durable three years after treatment; More biotech ...
Researchers at Kumamoto University have demonstrated that iron supplementation can significantly alleviate muscle pathology ...
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
GlobalData on MSN
Sarepta eyes Elevidys sales comeback with positive Phase III data
William Blair analysts view Elevidys’ three-year outcome as a win, though remain sceptical on the readout’s impact on sales ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on ...
After a roller coaster of a year for Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec), Sarepta Therapeutics Inc. looks to focus on the efficacy narrative in 2026, ...
Sarepta shares jump 5% after hours as company sets January 26 for 3-year Elevidys data following FDA safety warning and label restrictions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results